LSL. S. Shepelyaeva

L. S. Shepelyaeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


L. S. Shepelyaeva has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Why is therapeutic exercise the best treatment for knee osteoarthritis?

    by S. M. Noskov, V. A. Margazin, A. S. Bashkina, L. S. Shepelyaeva, O. M. Parulya, R. M. Nagibin

    Osteoarthritis (OA) of the knee joints (KJ) has a high social significance and is therefore a relevant pathology for scientific research. The authors have proposed an original hydraulic theory for the pathogenesis of OA in KJ. This approach is based on the notion of primary mechanical damage to the internal ligamentous structures and synovial membrane accompanied by posttraumatic edema, synovial hypervolemia, and hypertension. The authors demonstrated that regular physical activity at all stages of the disease is pathogenetically justified and allows the patient to improve lymphatic and venous outflow and thus resist increasing fibrosis. Improved arterial blood flow will reduce tissue hypoxia. Any type of symptom-modifying therapy can be harmful because it reduces the protective role of pain reflexes in protecting the KJ from excessive loads, leading to injury. The necessity of maintaining a walking speed of more than 4.3 km/h with an increase in cadence is emphasized from the perspective of reducing static stress during walking and extending life expectancy.


  • Open Access

    Bone marrow edema in osteoarthritis of the knee joint

    by S. M. Noskov, А. V. Snigireva, О. М. Parulya, L. S. Shepelyaeva, А. А. Mikryukov

    The term "bone marrow edema" (BME) in MRI examination of the knee joint is used to describe areas of decreased signal intensity on T1-weighted images or increased signal intensity on T2-weighted images in the subchondral bone. BME is classified into ischemic (osteonecrosis), mechanical (trauma), and reactive (arthritis) types. In this review, the causes and differences in BME with spontaneous and secondary osteonecrosis and other characteristics of BME transitioning to a syndrome are considered. BME with injuries and bruises is usually reversible and passes after approximately 2–4 months, if accompanied by a cortical fracture, after 6–12 months. A fatigue fracture develops as a result of repeated overloading of normal bone structures, whereas fractures in zones of subchondral bone insufficiency spontaneously occur in pathologically changed bone tissues (for example, osteoporotic bones) without any trauma or overloading. Histological examination of the damaged subchondral bone in ischemic and mechanical BME revealed hemorrhages, microdestruction of bone trabeculae and vascular anomalies, and almost complete absence of direct edema in MRI-positive zones due to increased extracellular fluid content, which can be partially explained by methodological difficulties in detecting increased extracellular fluid by histopathological methods. Prostacyclin and bisphosphonate have been proposed as conservative therapies for ischemic and mechanical BME.In osteoarthritis (OA) of the knee joints, BME is considered a marker of rapid progression. Data on the influence of obesity, therapeutic exercise and diet, and the use of a cane on BME are presented. Analysis of the effectiveness of conservative therapy revealed a weakly positive response to bisphosphonates. Inhibitors of nerve growth factor (NGF) — monoclonal antibodies to nerve growth factor (like tanezumab and fulranumab) — reduced the severity of pain but led to an increase in the frequency of osteonecrosis and endoprosthesis. Two studies have shown a decrease in the intensity of BME with oral chondroitin sulfate. The attention of orthopedists is focused on subchondroplasty using calcium phosphates. Subchondral filling, which strengthens the bone and replaces the lost barrier function of cartilage, has a symptomatic effect and effectively counteracts the development of BME, although the long-term results need to be studied.